What is a comprehensive clerkship—including focused history, physical examination, investigations, and management—for a patient with pulmonary tuberculosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Comprehensive Clerkship for Pulmonary Tuberculosis

For a patient with pulmonary TB, conduct a systematic evaluation focusing on TB-specific symptoms (chronic cough >2 weeks, hemoptysis, night sweats, weight loss), obtain three sputum specimens for AFB smear and culture with rapid molecular testing (NAAT), perform baseline chest radiography, and initiate standard four-drug therapy (rifampin, isoniazid, pyrazinamide, ethambutol) while establishing directly observed therapy and monthly monitoring protocols 1, 2.

Focused History

TB-Specific Symptoms

  • Respiratory: Chronic cough lasting >2 weeks, hemoptysis, dyspnea
  • Constitutional: Fever, night sweats, weight loss, fatigue, anorexia
  • Duration: Document symptom timeline (TB symptoms are typically prolonged, not acute)

Risk Factor Assessment

  • Exposure history: Contact with known TB cases, congregate living settings (prisons, shelters, nursing homes)
  • Geographic origin: Birth or residence in high-prevalence areas (Asia, Africa, Latin America)
  • Immunocompromised states: HIV status, diabetes mellitus, chronic renal insufficiency, immunosuppressive medications, malnutrition
  • Social factors: Homelessness, substance abuse (injection drug use), incarceration history
  • Previous TB: Prior TB infection or treatment, adherence to past regimens

Medication History

  • Current medications (assess for drug interactions with anti-TB therapy)
  • Alcohol consumption (hepatotoxicity risk)
  • History of liver disease, hepatitis B/C

Physical Examination

Vital Signs

  • Weight: Document baseline for medication dosing and monthly monitoring
  • Fever: Often low-grade and persistent
  • Respiratory rate: Tachypnea suggests severe disease

Pulmonary Examination

  • Auscultation: Crackles (typically apical), decreased breath sounds, wheezing (if bronchial involvement), signs of consolidation
  • Percussion: Dullness over affected areas
  • Inspection: Cachexia, respiratory distress

Extrapulmonary Signs

  • Lymphadenopathy: Cervical, supraclavicular nodes (suggests extrapulmonary spread)
  • Hepatosplenomegaly: Disseminated disease
  • Neurological: Altered mental status, meningismus (TB meningitis)
  • Musculoskeletal: Spinal tenderness (Pott's disease)

Investigations

Microbiological Testing (Priority)

Three sputum specimens for AFB smear and culture are essential 1:

  • First specimen: Immediate spot collection (sensitivity 53.8%)
  • Second specimen: Early morning collection next day (adds 11.1% sensitivity)
  • Third specimen: Another early morning collection (adds 2-5% sensitivity)
  • Rapid molecular testing (NAAT-TB): At least one baseline specimen must undergo nucleic acid amplification testing within 1 day for rapid confirmation of Mycobacterium tuberculosis complex 1
  • Drug susceptibility testing: Obtain for isoniazid, rifampin, ethambutol, and pyrazinamide on all baseline specimens 2
  • Molecular resistance testing (NAAT-R): Perform for patients with risk factors for drug resistance (prior TB treatment, contact with drug-resistant case, high-prevalence areas) 1

Imaging

  • Baseline chest radiograph: Mandatory for all patients 2
    • Classic findings: Upper lobe infiltrates, cavitation, nodules, fibrosis
    • Atypical patterns in immunocompromised patients
  • Chest CT with airway reconstruction: If tracheobronchial TB suspected (persistent cough, wheezing, stridor)
  • Month 2 chest radiograph: If baseline cultures are negative 2

Baseline Laboratory Testing 2

  • HIV testing: Mandatory for all TB patients with CD4 count and viral load if positive
  • Hepatitis B and C screening: For patients with risk factors (injection drug use, birth in Asia/Africa, HIV infection)
  • Liver function tests (ALT, AST, bilirubin): Baseline for all patients
  • Renal function (creatinine, BUN): Baseline for all patients
  • Complete blood count: Baseline assessment
  • Fasting glucose or HbA1c: For patients with diabetes risk factors (age >45, BMI >25, first-degree relative with diabetes, high-risk ethnicity)

Ophthalmologic Assessment

  • Baseline visual acuity (Snellen test) and color discrimination: Required before starting ethambutol 2

Management

Anti-Tuberculosis Treatment

Standard four-drug regimen for drug-susceptible pulmonary TB 2:

Intensive Phase (2 months)

  • Rifampin: 10 mg/kg/day (max 600 mg)
  • Isoniazid: 5 mg/kg/day (max 300 mg)
  • Pyrazinamide: 25 mg/kg/day (max 2000 mg)
  • Ethambutol: 15-20 mg/kg/day (max 1600 mg)

Continuation Phase (4 months)

  • Rifampin: 10 mg/kg/day (max 600 mg)
  • Isoniazid: 5 mg/kg/day (max 300 mg)

Total treatment duration: 6 months for drug-susceptible pulmonary TB

Directly Observed Therapy (DOT)

Implement DOT for all patients to ensure adherence 2:

  • Daily observation of medication ingestion
  • Outreach workers (bilingual/bicultural as needed)
  • Transportation assistance
  • Social service referrals (substance abuse treatment, housing)

Monitoring Protocol

Monthly Assessments 2

  • Sputum for AFB smear and culture: Monthly until two consecutive specimens are negative
  • Weight monitoring: Adjust medication doses if needed
  • Symptom assessment: Improvement in cough, fever, fatigue, night sweats
  • Adverse effect monitoring: Jaundice, dark urine, nausea, vomiting, abdominal pain, rash, peripheral neuropathy, arthralgias
  • Visual symptoms: Monthly inquiry about visual disturbance and color discrimination testing (for patients on ethambutol)
  • Adherence assessment: Document missed doses, barriers to adherence

Liver Function Monitoring 2

  • Routine monitoring NOT required unless:
    • Baseline abnormalities present
    • Symptoms of hepatotoxicity develop
    • Chronic alcohol consumption
    • Concurrent hepatotoxic medications
    • Viral hepatitis or liver disease history
    • HIV infection

Repeat Drug Susceptibility Testing

  • If patient remains culture-positive after 3 months of treatment 2

Management of Treatment Interruptions 2

During Intensive Phase:

  • Lapse <14 days: Continue treatment to complete planned doses (within 3 months)
  • Lapse ≥14 days: Restart treatment from beginning

During Continuation Phase:

  • Received ≥80% doses + initially AFB smear-negative: Continue until all doses completed
  • Received ≥80% doses + initially AFB smear-positive: Continue full course (unless consecutive lapse >2 months)
  • Received <80% doses + lapse <3 months: Restart if cannot complete within recommended timeframe
  • Received <80% doses + lapse ≥3 months: Restart entire treatment (new intensive and continuation phases)

Infection Control

  • Airborne isolation: Until patient has three consecutive negative AFB smears on different days
  • N95 respirators: For healthcare workers entering patient room
  • Negative pressure room: When available
  • Patient education: Cough etiquette, mask wearing

Contact Investigation

  • Report case to public health authorities immediately
  • Identify close contacts: Household members, coworkers, congregate setting contacts
  • Contact screening: TST or IGRA, chest radiography for symptomatic contacts

Special Considerations

HIV-Positive Patients 2

  • Initiate antiretroviral therapy (ART) within 2 weeks of starting TB treatment
  • Monitor for immune reconstitution inflammatory syndrome (IRIS)
  • Drug interaction management: Rifampin reduces antiretroviral drug levels; consider rifabutin substitution

Diabetes Mellitus

  • Optimize glycemic control: Improves TB treatment outcomes
  • Monitor glucose closely: Rifampin may affect diabetic medication efficacy

Pregnancy

  • Continue TB treatment: Benefits outweigh risks
  • Avoid pyrazinamide in first trimester (some guidelines)
  • Pyridoxine supplementation: 25-50 mg daily with isoniazid

Common Pitfalls to Avoid

  1. Do not use TST or IGRA to exclude active TB: These tests assess latent infection, not active disease 1
  2. Do not delay treatment waiting for culture results: Initiate therapy based on clinical suspicion and AFB smear results
  3. Do not stop ethambutol prematurely: Continue until drug susceptibility confirms susceptibility to isoniazid and rifampin
  4. Do not miss drug-resistant TB: Always obtain baseline drug susceptibility testing
  5. Do not overlook adherence barriers: Address social determinants (housing, transportation, substance abuse) proactively
  6. Do not forget HIV testing: Mandatory for all TB patients given high co-infection rates and treatment implications

Adjunctive Therapies

  • Pyridoxine (Vitamin B6): 25-50 mg daily to prevent isoniazid-induced peripheral neuropathy (especially for patients with diabetes, HIV, malnutrition, pregnancy, alcohol use)
  • Nutritional support: Early enteral nutrition for malnourished patients improves outcomes

This systematic approach ensures comprehensive evaluation, accurate diagnosis, appropriate treatment initiation, and rigorous monitoring to optimize patient outcomes while preventing transmission and drug resistance.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.